News

Study of 99 pediatric patients found clinically significant CNVs in 30% of cases, supporting CMA as a first-tier test for developmental delay and ID.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

New research suggests shorter antimicrobial treatments for pediatric urinary tract infections may be effective, challenging traditional 10-day courses.

Can you guess the diagnosis?

Test your knowledge of updated AAP recommendations for genetic evaluation of children with developmental delay and intellectual disability.

A survey reveals pediatric providers' limited changes in emergency contraception practices post-Dobbs, highlighting knowledge gaps and barriers to prescribing.

Fifteen infants with suspected or confirmed infant botulism and a confirmed exposure to Byheart Whole Nutrition infant formula have been reported from 12 states.

The patient was discharged after symptoms improved with antiemetics and pain medications.

FDA grants Breakthrough Device Designation to GeneDx genome and exome tests supporting diagnosis of life-threatening genetic disorders.

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Long-term analysis of the PEDFIC studies presented at NASPGHAN 2025 demonstrated sustained reductions in bile acids and pruritus with odevixibat in FIC1 deficiency.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

At NASPGHAN 2025, investigators presented 52-week safety data from an ongoing phase 3 trial of linaclotide, the first approved treatment for patients aged 7 and older with IBS-C.

The American Academy of Pediatrics updates guidelines, allowing doxycycline use in young children for tick-borne infections, enhancing treatment options.

New research shows an increase in neurodevelopmental disorder risk among children exposed to maternal COVID-19 infection in utero.

A health system–wide lipid screening pathway significantly increased pediatric screening rates across a large primary care network.

FDA approves first irritable bowel syndrome with constipation (IBS-C) treatment, linaclotide (Linzess), for children aged 7 years and older based on pediatric and adult trial data.

A multicenter study from NASPGHAN 2025 highlights geographic and immune-driven variations in pediatric H. pylori infection across the Americas.

Children face increasing eco-anxiety due to climate change, impacting their mental health. Pediatric healthcare providers play a crucial role in supporting their resilience.

Ruth Lynfield, MD, discusses an approach clinicians can take in counseling parents who may have concerns about vaccines.

New 2025 AHA CPR guidelines update choking response, opioid overdose care, and pediatric training to improve survival outcomes.

FDA approves Kygevvi, the first therapy for thymidine kinase 2 deficiency, a rare mitochondrial disease marked by muscle weakness and early death.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from October 2025.

If approved, this UC indication would add to pediatric indications of ustekinumab for psoriasis and active psoriatic arthritis.

Take a quick look at everything you may have missed this month, including the top FDA approvals and latest clinical updates.

A review highlights the benefits and risks of artificial sweeteners in glycemic control, insulin sensitivity, and gut microbiota balance.

Explore groundbreaking therapies for type 1 diabetes that aim to delay onset, preserve β-cell function, and restore insulin independence.

“There was no effect of lenacapavir on either estrogen containing or testosterone-containing regimens, no decrement in estradiol or testosterone levels," said Jill Blumenthal, MD, MAS.